NasdaqGS - Delayed Quote • USD
Exelixis, Inc. (EXEL)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:55 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 14 | 14 | 16 | 14 |
Avg. Estimate | 0.24 | 0.31 | 1.25 | 1.49 |
Low Estimate | 0.11 | 0.19 | 1.04 | 1.1 |
High Estimate | 0.47 | 0.42 | 1.42 | 2.07 |
Year Ago EPS | 0.12 | 0.25 | 0.65 | 1.25 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 17 | 17 | 21 | 19 |
Avg. Estimate | 460.62M | 480.36M | 1.91B | 2.07B |
Low Estimate | 417.6M | 450M | 1.83B | 1.91B |
High Estimate | 521M | 547M | 1.97B | 2.27B |
Year Ago Sales | 408.79M | 469.85M | 1.83B | 1.91B |
Sales Growth (year/est) | 12.70% | 2.20% | 4.30% | 8.40% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.15 | 0.16 | 0.09 | 0.21 |
EPS Actual | 0.12 | 0.25 | 0 | 0.27 |
Difference | -0.03 | 0.09 | -0.09 | 0.06 |
Surprise % | -20.00% | 56.20% | -100.00% | 28.60% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.24 | 0.31 | 1.25 | 1.49 |
7 Days Ago | 0.24 | 0.31 | 1.25 | 1.47 |
30 Days Ago | 0.23 | 0.31 | 1.23 | 1.46 |
60 Days Ago | 0.23 | 0.31 | 1.21 | 1.45 |
90 Days Ago | 0.25 | 0.31 | 1.09 | 1.37 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 2 | 3 | 2 | 3 |
Up Last 30 Days | 6 | 5 | 7 | 5 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | EXEL | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 100.00% | -- | -- | 5.40% |
Next Qtr. | 24.00% | -- | -- | 10.90% |
Current Year | 92.30% | -- | -- | 4.50% |
Next Year | 19.20% | -- | -- | 13.10% |
Next 5 Years (per annum) | 19.00% | -- | -- | 10.94% |
Past 5 Years (per annum) | -4.31% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Downgrade | Barclays: Overweight to Equal-Weight | 4/11/2024 |
Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/10/2024 |
Maintains | RBC Capital: Outperform to Outperform | 2/7/2024 |
Maintains | Stifel: Hold to Hold | 2/2/2024 |
Maintains | Barclays: Overweight to Overweight | 1/30/2024 |
Initiated | BTIG: Buy | 12/19/2023 |
Related Tickers
INCY Incyte Corporation
51.68
+0.98%
REGN Regeneron Pharmaceuticals, Inc.
883.20
-0.84%
HALO Halozyme Therapeutics, Inc.
38.57
+0.29%
GMAB Genmab A/S
28.15
+2.51%
CYTK Cytokinetics, Incorporated
65.34
+0.83%
ACAD ACADIA Pharmaceuticals Inc.
16.71
+2.45%
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
JAZZ Jazz Pharmaceuticals plc
109.46
+1.89%
RVMD Revolution Medicines, Inc.
35.96
+1.78%
BBIO BridgeBio Pharma, Inc.
24.88
+2.26%